Molecularly Targeted Clinical Trials Matching Service
Although significant advances in cancer treatment have been made in recent years, not all patients can be effectively treated within the standard of care paradigm. Many patients are eligible for clinical trials participation, yet less than 3% are actually enrolled in a trial, according to an evaluation of the NCI Clinical Trial Cooperative Group surgical oncology trials database.1
The Caris Molecular Intelligence™ Clinical Trials Connector™ allows physicians to quickly identify and review clinical trial opportunities in real-time that are matched based on the results for each patient.
Clinical Trials Connector™:
- Examines thousands of open and enrolling clinical trials
- Matches clinical trials based on:
- Gender
- Age (date-of-birth)
- Tumor type
- Biomarker profile
- Includes interactive and customisable trial search filters by:
- Biomarker
- Therapy
- Phase of study
- Study location(s)
- Study sponsor
All suitable clinical trials are included in the CMI report for each patient profiled. Contact us so we can provide you with more detailed information on any of these trials.


References
- Stewart JH, Bertoni AG, Staten JL, et al. Participation in surgical oncology clinical trials: Gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007;14(12):3328-34.
CLINICAL DECISION MAKING IN ADVANCED CANCER
Caris Molecular Intelligence, “offers the most complete multiplatform profile with which favourable clinical outcome data were produced. These clinical outcome data clearly show that with the right approach to clinical use, the broader practice is well justified as the clinical benefit has been demonstrated.”
Capdevila J, Rojo F, Gonzalez-Martin A, et al. Molecular profiling for clinical decision making in advanced cancer: a clinical appraisal. Journal of Cancer Research and Treatment. 2017; 5(3): 77-85.

